New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2013
06:20 EDTCOH, RPRXStocks with implied volatility below IV index mean; RPRX COH
Stocks with implied volatility below IV index mean; Repros Therapeutics (RPRX), Coach (COH) according to iVolatility.
News For COH;RPRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
10:18 EDTCOHCoach October weekly calls active
Coach October weekly 34 and 35.4 calls are active on total call volume of 6700 contracts (400 puts) on speculation of activist investor stake. October weekly call option implied volatility is at 44, November is at 26, December is at 28, January is at 27; compared to its 26-week average of 28 according to Track Data. Active call volume suggests traders taking positions for large near term price movement.
09:42 EDTCOHRumor: Coach moves up on speculation of activist investor stake
Subscribe for More Information
October 29, 2014
09:51 EDTRPRXRepros Therapeutics to host investor and analyst day
Investor and Analyst Day to be held in New York on October 31 at 7:30 am.
October 28, 2014
17:01 EDTCOHOn The Fly: Closing Wrap
Stocks on Wall Street opened in positive territory despite two disappointing economic data points and a mixed report from social media giant Twitter (TWTR). The market moved in a narrow range for the opening half hour of trading but gained upside momentum following a much better than expected consumer confidence reading. The market continued to tack on points throughout the afternoon and closed at its highs, led by the Nasdaq, which gained 1.75% for the session. ECONOMIC EVENTS: In the U.S., durable goods orders fell 1.3% in September, significantly undershooting expectations for them to have rise 0.7% in the month. The S&P Case-Shiller home price report showed prices were lower on a seasonally adjusted basis in the month of August compared to the prior month. A reading of consumer confidence surged to a seven-year high of 94.5 in October from a revised 89.0 final reading for September. The Richmond Fed's manufacturing index rose 6 points to 20 in October, beating expectations for it to have pulled back to 10. COMPANY NEWS: Twitter (TWTR) sunk $4.78, or 9.84%, to $43.78 after the social media company reported in-line profit and higher than expected Q3 revenue, but also reported a slowdown in user growth and provided weaker than expected Q4 guidance. Following last night's report, the stock was downgraded at RBC Capital, Nomura and Bank of America Merill Lynch to "Hold" or equivalent ratings, while Stifel lowered its rating on Twitter shares to Sell from Hold... Shares of Pfizer (PFE) edged up 6c, or 0.21%, to $29.09 after the pharmaceutical giant reported third quarter adjusted earnings per share and revenue that were a bit better than expected and narrowed its fiscal year profit outlook. Of note, Pfizer said during its earnings conference call that while proposed rule changes have made "inversions" more difficult, that meaningful value from inversion deals can still exists on a "case-by-case" basis. Shares of AstraZeneca (AZN), which was previously a target of Pfizer, gained 67c, or 0.95%, to $71.43 following Pfizer's comments. MAJOR MOVERS: Among the notable gainers following their earnings reports were Whirlpool (WHR), which advanced $10.66, or 6.77%, to $168.06, Cummins (CMI), which gained $9.22, or 6.81%, to $144.59, and Cliffs Natural (CLF), which jumped $2.05, or 22.19%, to $11.29. Among the noteworthy losers was Kohlís (KSS), which dropped $3.89, or 6.64%, to $54.66 after the department store operatorís outlook for third quarter same store sales and fiscal 2014 profit missed expectations. Also lower were shares of Coach (COH), which fell $2.15, or 5.95%, to $34.00 after the luxury handbag and accessory maker reported sales declined 9% on a constant currency basis in its first quarter. INDEXES: The Dow rose 187.81, or 1.12%, to 17,005.75, the Nasdaq advanced 78.36, or 1.75%, to 4,564.29, and the S&P 500 gained 23.42, or 1.19%, to 1,985.05.
11:58 EDTCOHStocks with call strike movement; COH DOW
Subscribe for More Information
10:39 EDTCOHCoach hits fresh 52-week low following earnings, levels to watch
Shares earlier hit a fresh 52-week low at $33.25 following earnings that missed expectations. The $33 area has been a strong zone of support, notably in 2010, 2008, and 2006. Support below $33 is at $32.18. Resistance is at $34.93.
09:20 EDTCOHOn The Fly: Pre-market Movers
Subscribe for More Information
09:09 EDTCOHCoach sees annual financial improvement beginning in FY16
Subscribe for More Information
09:07 EDTCOHCoach sees low double digit decline in FY15 constant currency, reported sales
Subscribe for More Information
08:59 EDTCOHCoach says still targeting China sales of over $600M in FY15
Subscribe for More Information
08:11 EDTCOHCoach report Q1 EPS ex-items 53c, consensus 45c
07:02 EDTCOHCoach reports Q1 EPS 43c, consensus 45c
Subscribe for More Information
October 27, 2014
15:36 EDTCOHNotable companies reporting before tomorrow's open
Subscribe for More Information
October 23, 2014
14:00 EDTRPRXRepros Therapeutics volatility elevated as shares trade near two-year low
Repros Therapeutics overall option implied volatility of 158 is above its 26-week average of 93 according to Track Data, suggesting large price movement.
October 21, 2014
18:36 EDTRPRXOn The Fly: After Hours Movers
Subscribe for More Information
16:11 EDTRPRXRepros Therapeutics: Results from Androxal study exhibit positive safety profile
Repros Therapeutics reported results from a large, controlled, long-term safety study comparing Androxal to a placebo. In this study of Androxal, ZA-303, no new safety signals were identified, including no evidence of negative effects on bone mineral density. Over 79% of the Androxal-treated subjects had morning testosterone levels above 300 ng/dL after being treated for 12 months. The last patient completed this study in late September. The Company's planned NDA will include study ZA-303, which will provide a significant portion of the support of long-term safety by providing data from 141 subjects exposed for one year or more. Over 200 subjects reached this milestone in the entire exposure database. ICH guidance for drugs to treat non-life-threatening conditions suggests that a minimum of 100 subjects should be exposed to the drug for one year.
October 17, 2014
09:17 EDTRPRXOn The Fly: Pre-market Movers
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use